Analysis of trends over time in client characteristics at Minnesota (MN) HIV-1 antibody counseling and testing sites.

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Analysis of trends over time in client characteristics at Minnesota (MN) HIV-1 antibody counseling and testing sites.

Int Conf AIDS. 1989 Jun 4-9;5:89 (abstract no. M.A.P.70). Unique Identifier : AIDSLINE ICA5/00022789
Danila R; Shultz J; Osterholm M; Henry K; Simpson M; MacDonald K; MN Dept. of Health, MN, USA

Abstract: OBJECTIVE: To evaluate the role of Minnesota HIV-1 antibody counseling and testing site programs (CTS) in HIV-1 transmission prevention efforts. METHODS: CTS client demographic and risk factor data were analyzed for 18,483 CTS clients with HIV-1 serology from 7/85-6/88. RESULTS: The highest seroprevalence rates were in male homosexual/bisexual intravenous drug users (37 of 145; 26%) and homosexual/bisexual men (705 of 5,310; 13%). A significant decrease in seroprevalence for all clients was noted from 14.3% for the first six months of operation to 3.2% for the last six months (p less than 0.001). This corresponds to changes in client characteristics over time: 1) the number and proportion of female first-time clients who were at low risk for HIV-1 infection increased (p less than 0.001); 2) the number and proportion of homosexual/bisexual males decreased and correspondingly the number and proportion of low-risk heterosexual males increased (p less than 0.001); 3) for homosexual/bisexual males, a significant decline in HIV-1 antibody prevalence over time was noted (p less than 0.05). CONCLUSIONS: These data indicate that CTS programs in Minnesota have progressively served fewer clients at high risk for HIV-1 infection over time. Outreach programs that identify and serve persons at highest risk for HIV-1 infection may be a more effective use of limited public health resources.

Keywords: Adult Bisexuality *Counseling Demography Female Homosexuality Human HIV Infections/*EPIDEMIOLOGY/PREVENTION & CONTROL *HIV Seroprevalence Male Minnesota/*EPIDEMIOLOGY Substance Abuse, Intravenous ABSTRACT
900930
M9094764

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .